PARP1 and cancer: Thus, when evaluating a pan-cancer cohort, we found that by expanding our search to include several HR genes beyond those most frequently associated with PARP inhibitors, there may be several additional patient groups who also have genetic loss of HRD and may therefore also respond to PARP inhibition.